Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: A multicenter, double-blind, randomized study

Fertility and Sterility

Volumn 74, Issue 1, 2000, Pages 10-19

  Winkler, Ulrich H ^a   Altkemper, Rolf ^b   Kwee, Bernadette ^b   Helmond, Frans A ^c   Coelingh Bennink, Herjan J T ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Clinic of Gynaecology and Obstetrics   (Germany)

^c NV ORGANON   (Netherlands)

Author keywords

Coagulation; Continuous combined HRT; Estradiol; Fibrinolysis; Hemostasis; Norethindrone acetate; Tibolone; Tissue specific HRT

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; ESTRADIOL; ESTRIOL; KILOGEST; NORETHISTERONE ACETATE; PROTEIN C; PROTEIN S; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BREAST AUGMENTATION; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; MENIERE DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; VEIN THROMBOSIS;

AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; THROMBOEMBOLISM;

EID: 0033938299     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)00587-2     Document Type: Article

References (47)

1. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med. 316:1987;1105-1110.
2. Anderson FA, Brownell Wheeler H, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovich B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
3. Nordström M., Lindblad B., Bergqvist D., Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 232:1992;155-160.
4. The Boston Collaborative Drug Surveillance Program. Surgically confirmed gall bladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974;290:15-9.
5. Devor M., Barrett-Connor E., Renvall M., Feigal D., Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med. 92:1992;275-282.
6. Petitti D.B., Wingerd J., Pellegrin F., Ramcharan S. Risk of vascular disease in women. J Am Med Assoc. 242:1979;1150-1154.
7. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy II a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems . Obstet Gynecol. 54:1979;74-79.
8. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
9. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
10. Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
11. Pérez-Gutthann S, Garcí Rodríguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997;314:796-800.
12. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13.
13. Scarabin P.Y. Risk of venous thrombosis with hormone replacement therapy. Lancet. 348:1996;1668.
14. Vandenbroucke JP, Helmerhorst FM. Risk of venous thrombosis with hormone replacement therapy. Lancet 1996;348:972.
15. Winkler U.H. Effects of androgens on haemostasis. Maturitas. 24:1996;147-155.
16. van Wersch J.W.J., Ubachs J.M.H., van den Ende A., van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem. 32:1994;449-453.
17. Rosati D., Micheli S., Pinto S., Fedi S., Bruni V., Bucciantini S., et al. Changes in lipidic and hemostatic parameters induced by tibolone treatment. Thromb Res. 85:1997;273-278.
18. Walker I.D., Davidson J.F., Richards A., Yates R., McEwan H.P. The effect of the synthetic steroid ORG OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost. 53:1985;303-306.
19. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas. (suppl 1):1987;67-72.
20. Parkin DE, Smith D, Al Azzawi F, Lindsay R, Hart DM. Effects of long-term ORG OD 14 administration on blood coagulation in climacteric women. Maturitas 1987;9:95-101.
21. Bjarnason NH, Bjarnason K, Haarbo J, Coelingh Bennink HJT, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6.
22. Hänggi W., Lippuner K., Riesen W., Jaeger P., Birkhäuser M.H. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a) a randomised study . Br J Obstet Gynaecol. 104:1997;708-717.
23. Sporrong T., Mattsson LÅ, Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 97:1990;939-944.
24. Taskinen M.R., Puolakka J., Pyörälä T., Luotola H., Björn M., Kääriäinen J., Lahdenperä S., Ehnholm C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Arterioscler Thromb Vasc Biol. 16:1996;1215-1221.
25. Farish E., Spowart K., Barnes J.F., Fletcher C.D., Calder A., Brown A., Hart D.M. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis. 126:1996;77-84.
26. Hammar M., Cristau S., Nathorst-Böös J., Rud T., Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 105:1998;904-911.
27. Tikkanen M.J. The menopause and hormone replacement therapy lipids, lipoproteins, coagulation and fibrinolytic factors . Maturitas. 23:1996;209-216.
28. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 62:1991;1-8.
29. Kroon U.B., Silfverstolpe G., Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 71:1994;420-423.
30. Winkler UH, Krämer R, Kwee B, Schindler AE. Östrogensubstitution in der Postmenopause, Blutgerinnung und Fibrinolyse: Vergleich einer neuartigen transdermalen Östradiolbehandlung mit der oralen Therapie mit konjugierten Östrogenen. Zentralbl Gynakol 1995;117:540-8.
31. Ball M.J., Ashwell E., Gillmer M.D.G. Progestagen-only oral contraceptives comparison of the metabolic effects of levonorgestrel and norethisterone . Contraception. 44:1991;223-233.
32. Fotherby K. The progestogen-only pill and thrombosis. Br J Fam Plann. 15:1989;83-85.
33. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 24:1996;1-19.
34. Preston F.E., Burakowski B.K., Porter N.R., Malia R.G. The fibrinolytic response to stanozolol in normal subjects. Thromb Res. 22:1981;543-551.
35. Winkler UH, Billenkamp U, Schindler AE. Danazol und Hämostase-zur kardiovasculären Risikoevaluation eines schwach androgen wirksamen ethinyltestosterone derivates. Endometriose 1992;3:79-84.
36. Jaillard A.S., Hommel M., Mallaret M. Venous sinus thrombosis associated with androgens in a healthy young men. Stroke. 25:1994;212-213.
37. Mammen E.F. Androgens and antiandrogens. Gynecol Endocrinol. 7:(suppl):1993;79-86.
38. Knox A.M., Brophy B.P., Sage M.R. Case report cerebral venous thrombosis in association with hormonal supplement therapy . Clin Radiol. 41:1990;355-357.
39. Strachan R., Hughes D., Cowie R. Thrombosis of the straight sinus complicating hormone replacement therapy. Br J Neurosurg. 9:1995;805-808.
40. Cohen J. Epidemiological disasters. Hum Reprod. 11:1996;689-690.
41. Westhoff C.L. Oral contraceptives and venous thromboembolism should epidemiological associations drive clinical decision making? Contraception. 54:1996;1-3.
42. Davies M.J., Thomas A. Thrombosis and acute coronary artery lesions in sudden ischaemic death. N Engl J Med. 310:1984;1137-1140.
43. Meade T.W., Dyer S., Howarth D.J., Imeson J.D., Stirling Y. Antithrombin III and progoagulant activity sex differences and effects of the menopause . Br J Haematol. 74:1990;77-81.
44. Scarabin P.Y., Plu-Bureau G., Bara L., Bonithon-Kopp C., Guize L., Samama M.M. Haemostatic variables and menopausal status influence of hormone replacement therapy . Thromb Haemost. 70:1993;584-587.
45. Juhan-Vague I. Haemostatic parameters and vascular risk. Atherosclerosis. 124:(suppl):1996;S49-S55.
46. Grodstein F., Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 38:1995;199-210.
47. European Menopause Society. European consensus development conference on menopause. Hum Reprod 1996;11:975-9.